Recent phase 3 trials, such as CheckMate 722 and KEYNOTE-789, have revealed that the clinical efficacy of ICIs plus chemotherapy is not significant in patients with EGFR mutation-positive nonsquamous NSCLC [9, 10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.